- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07585058
Safety and Efficacy of Early Non-invasive Brain-Computer Interface-Based Rehabilitation in Acute Ischemic Stroke (SeeBCI)
Safety and Efficacy of Early Non-invasive Brain-Computer Interface-Based Rehabilitation Training in Patients With Acute Ischemic Stroke: The SeeBCI Study
This is a single-center, prospective, randomized, sham-controlled pilot clinical study designed to evaluate the efficacy, safety, and feasibility of early non-invasive electroencephalography-based brain-computer interface (EEG-BCI) rehabilitation training in patients with acute ischemic stroke.
Eligible participants are adults aged 18 to 80 years with acute ischemic stroke, unilateral upper extremity motor impairment on the dominant-hand side, a baseline Fugl-Meyer Assessment of the Upper Extremity (FMA-UE) score of 10 to 50, and confirmed clinical stability 48 to 72 hours after stroke onset.
Participants will be randomly assigned in a 1:1 ratio to receive either real EEG-BCI training plus standard early rehabilitation or sham BCI training plus standard early rehabilitation. Both groups will receive 10 days of training, with two sessions per day and approximately 30 minutes per session.
The primary outcome is the change in FMA-UE score from baseline to 30 days after randomization. Secondary outcomes include changes in FMA-UE, Action Research Arm Test (ARAT), National Institutes of Health Stroke Scale (NIHSS), Modified Barthel Index (MBI), and modified Rankin Scale (mRS). Safety outcomes include symptomatic intracranial hemorrhage, any intracranial hemorrhage, neurological deterioration, seizures, falls, cardiovascular events, and training-related adverse events.
This pilot study aims to provide preliminary evidence regarding the feasibility, safety, and potential efficacy of early EEG-BCI rehabilitation after acute ischemic stroke and to inform the design of future multicenter randomized controlled trials.
Visão geral do estudo
Status
Condições
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
- Nome: Wang Chen, MD
- Número de telefone: +86 531 68773274
- E-mail: chenwang@sph.com.cn
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Age 18 to 80 years.
- Diagnosis of acute ischemic stroke.
- Stroke onset to randomization within 48 to 72 hours.
- Meets predefined clinical stability criteria before randomization.
- Unilateral upper extremity motor impairment on the dominant-hand side.
- Baseline Fugl-Meyer Assessment of the Upper Extremity (FMA-UE) score between 10 and 50.
- Pre-stroke modified Rankin Scale (mRS) score ≤2.
- Written informed consent obtained from the participant or legally authorized representative.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Dobro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Real EEG-BCI Training + Standard Early Rehabilitation
Participants will receive real electroencephalography-based brain-computer interface (EEG-BCI) training combined with standard early rehabilitation. The EEG-BCI training uses upper extremity motor imagery or motor attempt tasks with real-time decoding of motor intention and virtual hand feedback. Training will be performed twice daily for approximately 30 minutes per session over 10 consecutive days (20 sessions in total). |
Non-invasive EEG-based brain-computer interface training combined with standard early rehabilitation. The intervention includes EEG signal acquisition, motor intention decoding, and real-time virtual hand feedback. Participants perform upper extremity motor imagery or motor attempt tasks. Training is delivered twice daily for approximately 30 minutes per session for 10 consecutive days. Participants in both groups will receive standard early rehabilitation according to clinical practice, including appropriate physical therapy, occupational therapy, task-oriented training, positioning, and other routine rehabilitation interventions. |
|
Comparador Falso: Sham BCI Training + Standard Early Rehabilitation
Participants will receive sham BCI training combined with standard early rehabilitation. The sham procedure will match the real EEG-BCI training in appearance, frequency, duration, and workflow, but the feedback will not be generated by real-time EEG-based motor intention decoding. Training will be performed twice daily for approximately 30 minutes per session over 10 consecutive days (20 sessions in total). |
Participants in both groups will receive standard early rehabilitation according to clinical practice, including appropriate physical therapy, occupational therapy, task-oriented training, positioning, and other routine rehabilitation interventions. Sham BCI training designed to maintain participant masking. The procedure matches real EEG-BCI training in device setup, training environment, frequency, duration, and workflow, but the feedback is not linked to the participant's real-time EEG motor intention decoding. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change in Fugl-Meyer Assessment of the Upper Extremity (FMA-UE) Score From Baseline to Day 30
Prazo: Baseline to Day 30 after randomization
|
The primary outcome is the change in FMA-UE score from baseline (T0) to 30 days after randomization. The FMA-UE evaluates upper extremity motor function after stroke, with scores ranging from 0 to 66. Higher scores indicate better upper extremity motor function. Change score is calculated as the FMA-UE score at Day 30 minus the baseline FMA-UE score. |
Baseline to Day 30 after randomization
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Fugl-Meyer Assessment of the Upper Extremity (FMA-UE) Score
Prazo: Baseline, Day 10, Day 30, and Day 90
|
Upper extremity motor function will be assessed using the FMA-UE. The total score ranges from 0 to 66, with higher scores indicating better motor function. |
Baseline, Day 10, Day 30, and Day 90
|
|
Action Research Arm Test (ARAT) Score
Prazo: Baseline, Day 30, and Day 90
|
Upper extremity activity performance will be assessed using the ARAT. The total score ranges from 0 to 57, with higher scores indicating better upper limb functional ability. |
Baseline, Day 30, and Day 90
|
|
National Institutes of Health Stroke Scale (NIHSS) Score
Prazo: Baseline, Day 10, and Day 30
|
Neurological impairment will be assessed using the NIHSS. Scores range from 0 to 42, with higher scores indicating greater neurological deficit. |
Baseline, Day 10, and Day 30
|
|
Modified Rankin Scale (mRS) Score
Prazo: Day 90
|
Global functional outcome will be assessed using the modified Rankin Scale. Scores range from 0 to 6, with higher scores indicating greater disability. |
Day 90
|
|
Modified Barthel Index (MBI) Score
Prazo: Day 30 and Day 90
|
Activities of daily living will be assessed using the Modified Barthel Index. Higher scores indicate better functional independence. |
Day 30 and Day 90
|
Outras medidas de resultado
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Training Completion Rate
Prazo: During the 10-day intervention period
|
Feasibility outcome defined as the proportion of completed EEG-BCI or sham BCI training sessions among the planned 20 sessions. |
During the 10-day intervention period
|
|
Effective Training Duration
Prazo: During the 10-day intervention period
|
Feasibility outcome defined as the cumulative duration of completed valid BCI training sessions during the intervention period. |
During the 10-day intervention period
|
|
EEG Signal Quality and BCI Performance Metrics
Prazo: During the 10-day intervention period
|
Feasibility outcome assessing EEG acquisition quality and available BCI performance metrics, including signal quality and classification accuracy when available. |
During the 10-day intervention period
|
|
Follow-up completion rate
Prazo: Through Day 90
|
Feasibility outcome defined as the proportion of randomized participants who complete scheduled outcome assessments through Day 90. |
Through Day 90
|
|
Protocol deviation rate
Prazo: From randomization through Day 90
|
Feasibility outcome defined as the proportion of participants with one or more protocol deviations. |
From randomization through Day 90
|
|
Incidence of symptomatic intracranial hemorrhage
Prazo: From baseline through Day 90
|
Safety outcome defined as the occurrence of symptomatic intracranial hemorrhage after randomization. |
From baseline through Day 90
|
|
Incidence of any intracranial hemorrhage
Prazo: From baseline through Day 90
|
Safety outcome defined as the occurrence of any type of intracranial hemorrhage after randomization. |
From baseline through Day 90
|
|
Incidence of neurological deterioration
Prazo: From baseline through Day 90
|
Safety outcome defined as clinically relevant neurological worsening after randomization, such as an increase in NIHSS score of 4 or more points without another clear explanation. |
From baseline through Day 90
|
|
Incidence of seizures
Prazo: From baseline through Day 90
|
Safety outcome defined as the occurrence of seizure events after randomization. |
From baseline through Day 90
|
|
Incidence of Falls or Injuries
Prazo: From baseline through Day 90
|
Safety outcome defined as the occurrence of falls during the study period. |
From baseline through Day 90
|
|
Incidence of Cardiovascular and Vital Sign Events
Prazo: From baseline through Day 90
|
Safety outcome defined as the occurrence of clinically relevant blood pressure instability or cardiac arrhythmia events during the study period. |
From baseline through Day 90
|
|
Incidence of training-related discomfort
Prazo: During the 10-day intervention period
|
Safety outcome defined as the occurrence of training-related discomfort, including fatigue, headache, dizziness, nausea, skin irritation, or other discomfort associated with the intervention. |
During the 10-day intervention period
|
|
Incidence of serious adverse events
Prazo: From baseline through Day 90
|
Safety outcome defined as the occurrence of serious adverse events (SAEs), including death, life-threatening events, hospitalization or prolongation of hospitalization, persistent or significant disability, or other medically important events. |
From baseline through Day 90
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: QinJian Sun, MD, Shandong Provincial Hospital
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- SWYX.NO.2026-1053
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .